Annual EBITDA
$9.88 M
-$23.66 M-70.55%
31 December 2023
Summary:
Pharming Group NV annual earnings before interest, taxes, depreciation & amortization is currently $9.88 million, with the most recent change of -$23.66 million (-70.55%) on 31 December 2023. During the last 3 years, it has fallen by -$48.48 million (-83.07%). PHAR annual EBITDA is now -86.18% below its all-time high of $71.46 million, reached on 31 December 2019.PHAR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$7.25 M
+$5.34 M+279.05%
30 September 2024
Summary:
Pharming Group NV quarterly earnings before interest, taxes, depreciation & amortization is currently $7.25 million, with the most recent change of +$5.34 million (+279.05%) on 30 September 2024. Over the past year, it has increased by +$2.44 million (+50.83%). PHAR quarterly EBITDA is now -80.18% below its all-time high of $36.61 million, reached on 30 September 2017.PHAR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$6.89 M
+$2.44 M+55.02%
30 September 2024
Summary:
Pharming Group NV TTM earnings before interest, taxes, depreciation & amortization is currently $6.89 million, with the most recent change of +$2.44 million (+55.02%) on 30 September 2024. Over the past year, it has increased by +$16.66 million (+170.50%). PHAR TTM EBITDA is now -91.89% below its all-time high of $84.90 million, reached on 30 September 2020.PHAR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PHAR EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -70.5% | +50.8% | +170.5% |
| 3 y3 years | -83.1% | +45.4% | -71.2% |
| 5 y5 years | -60.3% | -66.7% | -82.7% |
PHAR EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -83.1% | at low | -68.4% | +162.7% | -88.4% | +170.5% |
| 5 y | 5 years | -86.2% | at low | -71.8% | +162.7% | -91.9% | +170.5% |
| alltime | all time | -86.2% | +112.9% | -80.2% | +107.7% | -91.9% | +109.0% |
Pharming Group NV EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $7.25 M(+279.0%) | $6.89 M(+55.0%) |
| June 2024 | - | $1.91 M(-120.9%) | $4.44 M(-52.0%) |
| Mar 2024 | - | -$9.15 M(-233.2%) | $9.25 M(+35.5%) |
| Dec 2023 | $9.88 M(-70.5%) | $6.87 M(+42.8%) | $6.83 M(-169.9%) |
| Sept 2023 | - | $4.81 M(-28.4%) | -$9.77 M(+365.3%) |
| June 2023 | - | $6.72 M(-158.1%) | -$2.10 M(-114.8%) |
| Mar 2023 | - | -$11.57 M(+18.9%) | $14.16 M(-57.8%) |
| Dec 2022 | $33.53 M(-31.3%) | -$9.73 M(-178.0%) | $33.53 M(-43.5%) |
| Sept 2022 | - | $12.48 M(-45.7%) | $59.36 M(+14.4%) |
| June 2022 | - | $22.98 M(+194.5%) | $51.87 M(+29.3%) |
| Mar 2022 | - | $7.80 M(-51.5%) | $40.13 M(-17.7%) |
| Dec 2021 | $48.78 M(-16.4%) | $16.10 M(+222.7%) | $48.78 M(+103.8%) |
| Sept 2021 | - | $4.99 M(-55.6%) | $23.94 M(-46.4%) |
| June 2021 | - | $11.23 M(-31.7%) | $44.70 M(-12.2%) |
| Mar 2021 | - | $16.45 M(-288.3%) | $50.92 M(-12.7%) |
| Dec 2020 | $58.35 M(-18.3%) | -$8.74 M(-133.9%) | $58.35 M(-31.3%) |
| Sept 2020 | - | $25.75 M(+47.5%) | $84.90 M(+4.9%) |
| June 2020 | - | $17.46 M(-26.9%) | $80.95 M(+1.3%) |
| Mar 2020 | - | $23.88 M(+34.1%) | $79.91 M(+11.8%) |
| Dec 2019 | $71.46 M(+187.5%) | $17.81 M(-18.3%) | $71.46 M(+79.1%) |
| Sept 2019 | - | $21.79 M(+32.7%) | $39.90 M(+10.1%) |
| June 2019 | - | $16.42 M(+6.4%) | $36.25 M(+25.0%) |
| Mar 2019 | - | $15.44 M(-212.3%) | $29.01 M(+16.7%) |
| Dec 2018 | $24.85 M(-132.6%) | -$13.74 M(-175.8%) | $24.85 M(-144.7%) |
| Sept 2018 | - | $18.14 M(+97.7%) | -$55.66 M(+49.6%) |
| June 2018 | - | $9.17 M(-18.7%) | -$37.20 M(-46.9%) |
| Mar 2018 | - | $11.28 M(-112.0%) | -$70.08 M(-8.2%) |
| Dec 2017 | -$76.33 M(+450.1%) | -$94.26 M(-357.5%) | -$76.33 M(-642.0%) |
| Sept 2017 | - | $36.61 M(-254.4%) | $14.08 M(-153.1%) |
| June 2017 | - | -$23.71 M(-571.0%) | -$26.52 M(+389.4%) |
| Mar 2017 | - | $5.03 M(-230.9%) | -$5.42 M(-60.9%) |
| Dec 2016 | -$13.88 M | -$3.85 M(-3.8%) | -$13.88 M(+44.9%) |
| Sept 2016 | - | -$4.00 M(+53.0%) | -$9.58 M(+8.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2016 | - | -$2.61 M(-23.7%) | -$8.83 M(-7.7%) |
| Mar 2016 | - | -$3.42 M(-855.8%) | -$9.57 M(+2.8%) |
| Dec 2015 | -$9.31 M(+36.9%) | $452.70 K(-113.9%) | -$9.31 M(+116.5%) |
| Sept 2015 | - | -$3.25 M(-2.9%) | -$4.30 M(-27.4%) |
| June 2015 | - | -$3.35 M(+5.8%) | -$5.92 M(+2.8%) |
| Mar 2015 | - | -$3.16 M(-157.9%) | -$5.76 M(-15.3%) |
| Dec 2014 | -$6.80 M(-57.9%) | $5.46 M(-212.2%) | -$6.80 M(-71.9%) |
| Sept 2014 | - | -$4.87 M(+52.8%) | -$24.22 M(+5.1%) |
| June 2014 | - | -$3.19 M(-24.2%) | -$23.05 M(+26.4%) |
| Mar 2014 | - | -$4.20 M(-64.8%) | -$18.24 M(+13.0%) |
| Dec 2013 | -$16.13 M(-43.3%) | -$11.96 M(+223.7%) | -$16.13 M(+49.0%) |
| Sept 2013 | - | -$3.69 M(-328.1%) | -$10.83 M(-24.9%) |
| June 2013 | - | $1.62 M(-177.2%) | -$14.41 M(-41.9%) |
| Mar 2013 | - | -$2.10 M(-68.5%) | -$24.78 M(-12.8%) |
| Dec 2012 | -$28.43 M(+24.4%) | -$6.66 M(-8.5%) | -$28.43 M(+7.5%) |
| Sept 2012 | - | -$7.28 M(-16.9%) | -$26.44 M(+7.4%) |
| June 2012 | - | -$8.75 M(+52.4%) | -$24.63 M(+9.3%) |
| Mar 2012 | - | -$5.75 M(+23.1%) | -$22.53 M(-1.4%) |
| Dec 2011 | -$22.85 M(-53.3%) | -$4.67 M(-14.6%) | -$22.85 M(-52.0%) |
| Sept 2011 | - | -$5.47 M(-17.9%) | -$47.64 M(-6.7%) |
| June 2011 | - | -$6.65 M(+9.7%) | -$51.08 M(+2.2%) |
| Mar 2011 | - | -$6.06 M(-79.4%) | -$49.99 M(-1.2%) |
| Dec 2010 | -$48.95 M(+45.7%) | -$29.45 M(+230.5%) | -$50.61 M(+69.5%) |
| Sept 2010 | - | -$8.91 M(+60.3%) | -$29.85 M(-0.3%) |
| June 2010 | - | -$5.56 M(-16.8%) | -$29.94 M(-3.5%) |
| Mar 2010 | - | -$6.68 M(-23.2%) | -$31.03 M(-5.7%) |
| Dec 2009 | -$33.58 M(+44.5%) | -$8.70 M(-3.3%) | -$32.92 M(+35.9%) |
| Sept 2009 | - | -$9.00 M(+35.3%) | -$24.22 M(+59.2%) |
| June 2009 | - | -$6.65 M(-22.4%) | -$15.22 M(+77.6%) |
| Mar 2009 | - | -$8.57 M | -$8.57 M |
| Dec 2008 | -$23.25 M(-16.4%) | - | - |
| Dec 2007 | -$27.81 M(+31.3%) | - | - |
| Dec 2006 | -$21.17 M(+10.8%) | - | - |
| Dec 2005 | -$19.11 M | - | - |
FAQ
- What is Pharming Group NV annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Pharming Group NV?
- What is Pharming Group NV annual EBITDA year-on-year change?
- What is Pharming Group NV quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Pharming Group NV?
- What is Pharming Group NV quarterly EBITDA year-on-year change?
- What is Pharming Group NV TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Pharming Group NV?
- What is Pharming Group NV TTM EBITDA year-on-year change?
What is Pharming Group NV annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of PHAR is $9.88 M
What is the all time high annual EBITDA for Pharming Group NV?
Pharming Group NV all-time high annual earnings before interest, taxes, depreciation & amortization is $71.46 M
What is Pharming Group NV annual EBITDA year-on-year change?
Over the past year, PHAR annual earnings before interest, taxes, depreciation & amortization has changed by -$23.66 M (-70.55%)
What is Pharming Group NV quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of PHAR is $7.25 M
What is the all time high quarterly EBITDA for Pharming Group NV?
Pharming Group NV all-time high quarterly earnings before interest, taxes, depreciation & amortization is $36.61 M
What is Pharming Group NV quarterly EBITDA year-on-year change?
Over the past year, PHAR quarterly earnings before interest, taxes, depreciation & amortization has changed by +$2.44 M (+50.83%)
What is Pharming Group NV TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of PHAR is $6.89 M
What is the all time high TTM EBITDA for Pharming Group NV?
Pharming Group NV all-time high TTM earnings before interest, taxes, depreciation & amortization is $84.90 M
What is Pharming Group NV TTM EBITDA year-on-year change?
Over the past year, PHAR TTM earnings before interest, taxes, depreciation & amortization has changed by +$16.66 M (+170.50%)